II-VI IIVI
July 07, 2010 - 4:21pm EST by
tumnus960
2010 2011
Price: 29.70 EPS $1.20 $1.77
Shares Out. (in M): 31 P/E 23.3x 15.2x
Market Cap (in $M): 927 P/FCF 16.8x 13.9x
Net Debt (in $M): -94 EBIT 50 76
TEV (in $M): 833 TEV/EBIT 16.6x 11.0x

Sign up for free guest access to view investment idea with a 45 days delay.

Description

Introduction
 
II-VI enjoys competitive advantages in producing optical components for industrial, medical, and military laser systems due to its vertical integration into crystal growth which gives it higher quality and lower cost raw materials than its competitors.  At $29.70, IIVI is trading at 15.2x earnings, which is the bottom of its historic multiple range which typically spans from 15x to 25x and averages around 20x.  Historically, periods corresponding to the bottom of this range have proven a good time to buy the stock, and this time offers the additional benefit of positive developments that are starting to unfold in a number of IIVI's divisions. 

IIVI's FYE is June 30.

Background

II-VI ("Two-Six") was founded in 1971 by an engineer who believed that materials used in the laser systems of that time were sub-optimal and could be improved upon by instead using "Two Six" compounds-compounds made from elements in columns 2 and 6 of the Periodic Table of Elements.  He was proven right, and II-VI grew into the leading supplier of optical components for high-power industrial CO2 lasers.

Today, IIVI produces a wide range of optical components for diverse laser applications.  Over the last 15 years, the laser industry has grown significantly as lasers have displaced traditional tools used for cutting, drilling, punching, marking, welding, ablating, cladding, and heat treating.  In general, lasers are faster, more precise, and more reliable than the saws, drills, and other tools they are replacing.  In addition, laser processing is often cheaper since it enables a greater degree of automation than conventional methods.  Prior to the downturn, roughly 4,000 to 5,000 new industrial laser systems were being fielded annually.  Lasers' use has also grown in medical and military applications.

IIVI produces the beam delivery components of a laser system, such as the mirrors that help move the beam, lenses to focus the beam, and in some cases, the crystals that generate the beam.  Importantly, these components wear out with use, and in a factory environment, the optics need to be replaced every 100-200 hours.  (One of John Deere's plants has a vending machine that has been retrofitted to dispense optics instead of snacks, and IIVI replenishes this machine once a month.)  In a cleaner setting such as a hospital, optics can last for years.  IIVI sells to both laser OEM's and end users, though ongoing replacement demand from a growing installed base has progressively increased IIVI's exposure to the aftermarket.  IIVI's Infrared Optics segment is it's most heavily focused on industrial applications, and they estimate that roughly 90% of this segment's sales are tied to the aftermarket.  (In North America, the Infrared Optics segment serves the aftermarket directly, but outside of North America, customers prefer to buy optics through the laser OEM's, so it's difficult for IIVI to know how much of the content in those markets is split between newbuild systems and replacement demand.)  In IIVI's other three segments, roughly 50% of revenue comes from the aftermarket.

IIVI's competitive position varies somewhat by division, but in general, each division derives competitive advantages from a few key areas.  The first and most significant is their ability to grow their own crystals, which is the first step in optics production.  It takes roughly a decade to get down the basic process for growing a particular crystal, and even after that, the process is far from a hard science.  Even today, IIVI's R&D and manufacturing groups continue to collaborate extensively in the pursuit of higher yields, larger crystals, and lower costs.  The growth processes are also capital intensive and temperamental.  For example, in one of IIVI's crystal growth processes, the crystals can't be without power for more than 5 seconds at a time during a 30-35 day growth cycle.  As you might expect, such challenging processes occasionally result in yield problems, and the resulting earnings "slip ups" provide excellent opportunities to get into the stock.  Such challenges, however, have also resulted in limited competition, and growing its own crystals provides IIVI with important cost and quality advantages over its competitors.

IIVI's second competitive advantage is in precision manufacturing (i.e. fabricating the raw crystal into an optic, polishing that optic, and coating the optic to enhance it's natural properties).  As lasers have become increasingly powerful, the optics need surfaces that are progressively smoother, and IIVI is one of the only companies in the world that's able to fabricate and polish these temperamental materials to this level of precision.  Because the materials are difficult to work with, customers sometimes also delegate sub-assembly to IIVI since IIVI's optics expertise results in higher sub-assembly yields than the customers would be able to achieve on their own. 

Finally, I believe that management's long-term orientation and ability to absorb the inevitable bumps along the way is also a competitive advantage.  Few managements appear willing to undertake the multi-year, methodical incubation and development periods that IIVI has pursued and continues to advance. 

Business Segments

IIVI is organized around four segments, all of which currently have favorable dynamics that should translate into better results going forward.  IIVI's largest and most profitable segment is its Infrared Optics (IRO) segment.  IRO was IIVI's original business and produces Zinc-based materials and optics, including Zinc Selenide which is the best compound for transmitting energy from CO2 lasers.  IIVI is the largest producer and consumer of Zinc Selenide in the world, and it's competitive advantages in this area have made it the clear market leader with over 50% marketshare.  The main application of these materials is in CO2 lasers which are principally used in industrial applications such as cutting, though there are also military applications such as components for infrared cameras.

IIVI's second largest business is its Near Infrared Optics business (NIRO).  This division addresses various niches within the near infrared market and serves medical, industrial, scientific and military applications.  IIVI has a solid competitive position in this area, though it is not as pronounced as in the IRO division.

NIRO has undergone a number of significant changes in recent years.  In 2003, NIRO purchased a UV filter business from Coherent.  These UV filters could be used to detect missile plumes and provide an early warning system for military aircraft.  NIRO paid 2MM for this business and over the next five years realized 100MM of revenue (with apparently very good margins) selling into a program that retrofitted Apache helicopters with such equipment.  By FY08, that program had grown to roughly 40% of the segment's revenue, but it began to decline in FY09 and presented a significant multi-year headwind for that division.  Fortunately, they've been able to offset much of this UV business with non-UV military business which continues to grow. 

In January, 2010, IIVI announced the acquisition of Photop Technologies.  Photop is an optics producer that is based in China and will be included in the NIRO segment, more than doubling NIRO's revenues.  Photop's optics are somewhat adjacent to IIVI, but the real motivation for the acquisition appears to be to expand IIVI's presence in China and to provide it with a more competitive cost structure in certain products.  NIRO has historically manufactured its products in Florida, but this left it with a cost structure that was too high to compete in Asia.  Many of the fabrication capabilities that Photop uses for telecom optics are the same ones that NIRO needs to produce its products for the Asian market, so Photop should enable NIRO to expand geographically.  Thus far, Photops revenues and margins have come in far ahead of expectation.

IIVI's third segment is it's Military & Materials segment (M&M).  This segment is really an amalgamation of two unrelated divisions.  The military side produces large scale optical components that prime military contractors use in imaging and targeting systems.  One exciting new program for this division is large area sapphire windows for the Joint Strike Fighter (JSF) that IIVI will produce on a sole source basis.  This division also recently unseated an incumbent and won a contract to provide the JSF with components for a missile early warning system.  The Materials side of M&M runs a recycling operation in the Philippines that extracts selenium and tellurium from other companies' waste streams.  IIVI acquired this operation in order to improve it's access to these two critical raw materials, and also to provide the IRO segment with lower cost selenium.  This division sells to external customers as well. 

IIVI's fourth segment is its Compound Semiconductor Group (CSG).  This segment's largest division makes Thermo Electric Coolers (TEC's) which are solid-state semiconductors that can be used to heat, cool, or stabilize the temperatures of other components or systems.  TEC's are used in a wide range of applications including military, telecom, medical, and consumer.  The CSG has also been incubating a division that produces Silicon Carbide crystals for emerging high performance military and telecom applications. 

Outlook

Over the long term, IIVI should continue to grow as lasers continue to proliferate in industrial, medical, and military applications.  In the short-to-medium term, all of IIVI's divisions should benefit from the economic recovery, as well as certain discrete drivers.  The IRO segment, for example, is benefiting from rebounding aftermarket demand (which is a leading indicator), but it is also benefiting from new product introductions and a margin recovery that has been a long time in the making.  In FY07 and FY08, IRO's operating margins were depressed by significant yield problems as well as high selenium prices.  IRO's yields had been restored by 1H09, and were at record levels by 3Q09, but it takes a few quarters for these to work through inventory and into COGS.  In addition, IRO's selenium costs should have begun to benefit from the Philippine recycling operation in late FY09, and then additionally from lower selenium market prices around mid-FY10.  (Mid-FY10 was the approximate time that lower market prices would begin to flow through to COGS.)  Lastly, the former yield problems noted above precluded IIVI from selling raw Zinc-based materials to third parties since it needed these materials for internal consumption.  Such sales to third parties are usually high margin, and IRO was able to re-enter this market in FY09.  During the downturn, IRO has been selling raw zinc-based materials at lower than normal prices in order to use otherwise idle capacity, but as the environment normalizes, I'd expect them to raise prices on these products.  It is difficult to be precise about when IRO's margins will be restored to the mid-20%'s or higher, but management has indicated that this improvement is on the horizon.  I suspect that we would have already seen more improvement if we were in a normal economic environment.

NIRO's non-UV military business is expected to continue ramping over the next twelve months.  The M&M's military business is beginning to benefit from "military reset" (i.e. repairing and overhauling all of the equipment that's begun to return from Iraq) as well as the initial ramp of the JSF.  Over the long-term, the JSF represents a very large opportunity for IIVI, though it is difficult to quantify since management believes that the military will eventually develop a second source of sapphire windows for this highly strategic weapons platform.  Lastly, the CSG's TEC business has a high volume program that had been expected to begin shipping in June quarter. 

Valuation

As shown in the table below, IIVI's stock has traded within a relatively predictable valuation range since FY03. 

Historic P/E Multiples

 

Low

Average

High

FY03

13.7

20.1

29.9

FY04

16.2

20.5

25.6

FY05

15.8

21.5

26.8

FY06

16.1

19.8

24.0

FY07

13.6

21.9

29.8

FY08

14.3

20.2

25.2

FY09

9.6

19.9

38.4

FY10*

13.8

22.0

29.5

*IIVI's FYE is June 30, so the stock price figures for FY10 are known, but the earnings are based on my most recent estimate.

Earnings should advance dramatically in FY11 as the overall economy continues to recover and the specific drivers mentioned above further advance IIVI's results.  My initial EPS estimate for FY11 is $1.77, and I wouldn't be surprised if that proves conservative.  At $29.70 (less $3.01 of cash per share), IIVI is thus trading at 15.2x, near the bottom of the historic range.

Lastly, I've included portions of my model below, including my long-term forecasts.  The expected annual stock returns under those forecasts may appear modest at only 10-15%, but it's important to note that I am being very conservative and assuming that the IRO division grows considerably slower in the future than it has in the past.  I'm also using conservative growth rates for the other three segments.  (My general approach is to look for situations where I can get a 10% return using assumptions that are likely to be proved conservative.)

II-VI                      
Fiscal Year End: June 30                      
In Millions, Except for Percentages & per Share Amounts            
Note: eV Products Classified as Discontinued Beginning FY06 & 3Q07          
                       
    FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09
                       
Total Sales   74.1 123.3 113.7 128.2 150.8 194.0 223.6 254.7 316.2 292.2
% Change (Yr./Yr.)   19.5% 66.5% -7.8% 12.8% 17.7% 28.6% 19.8% 13.9% 24.2% -7.6%
% Change (Seq.)                      
                       
COGS   41.6 72.2 69.7 69.4 79.6 104.9 125.9 138.2 176.5 168.6
Contract R&D   1.2 3.6 6.9 10.4 7.1 6.8 6.4 8.3 9.4 7.5
                       
Gross Profit   31.3 47.5 37.1 48.4 64.2 82.4 91.3 108.2 130.2 116.1
% of Sales   42.3% 38.5% 32.6% 37.7% 42.5% 42.5% 40.8% 42.5% 41.2% 39.7%
                       
Internal R&D   2.8 4.5 4.4 2.7 5.0 5.8 5.9 5.8 7.7 10.2
% of Sales   3.8% 3.6% 3.9% 2.1% 3.3% 3.0% 2.6% 2.3% 2.4% 3.5%
                       
SG&A   18.2 24.8 21.2 28.5 34.4 41.9 46.3 53.4 60.8 58.1
% of Sales   24.5% 20.1% 18.7% 22.2% 22.8% 21.6% 20.7% 21.0% 19.2% 19.9%
                       
Operating Income   10.3 18.3 11.4 17.2 24.8 34.6 39.2 49.0 61.7 47.8
% of Sales   13.9% 14.8% 10.0% 13.4% 16.5% 17.8% 17.5% 19.2% 19.5% 16.4%
                       
Interest Expense   0.3 2.3 1.4 0.8 0.4 0.9 1.8 1.0 0.2 0.2
Other Expense, Net   0.2 1.4 0.4 0.3 0.0 (0.3) (1.3) (2.7) (2.8) 1.4
Impairments & Other               16.8   (26.5)  
                       
EBT   9.8 14.6 9.5 16.1 24.4 34.0 21.8 50.7 90.6 46.3
% of Sales   13.2% 11.8% 8.4% 12.5% 16.2% 17.5% 9.8% 19.9% 28.7% 15.8%
                       
Income Tax Expense   2.4 5.1 2.2 4.4 7.1 9.1 10.7 12.2 24.9 7.4
Rate   25.1% 34.8% 23.6% 27.6% 29.0% 26.8% 49.2% 24.2% 27.5% 16.0%
                       
Minority Interests                      
                       
N.I. from Cont. Ops.   7.3 9.5 7.3 11.6 17.3 24.8 11.1 38.4 65.7 38.9
ex. Non-Rec.               28.0   49.8 35.8
                       
Earnings from Discont. Ops.               (0.3) (0.5) (1.4) (2.1)
                       
Net Income   7.3 9.5 7.3 11.6 17.3 24.8 10.8 38.0 64.3 36.8
ex. Non-Rec.               27.7   48.4 33.7
                       
Diluted EPS from Cont. Ops.   $0.28 $0.34 $0.25 $0.40 $0.59 $0.83 $0.37 $1.27 $2.15 $1.29
ex. Non-Rec.               $0.94   $1.63 $1.19
                       
Diluted EPS   $0.28 $0.34 $0.25 $0.40 $0.59 $0.83 $0.36 $1.25 $2.11 $1.22
ex. Non-Rec.               $0.93   $1.59 $1.12
                       
Diluted Shares Out.   26.4 28.3 28.6 28.8 29.4 29.9 29.9 30.3 30.5 30.1
                       
                       
Financial Ratios                      
ROS   9.9% 7.7% 6.4% 9.1% 11.5% 12.8% 12.5% 15.1% 15.7% 12.2%
Asset T/O   0.96 1.06 0.76 0.81 0.87 0.89 0.89 0.95 0.97 0.80
                       
ROA   9.4% 8.2% 4.8% 7.4% 10.0% 11.4% 11.1% 14.3% 15.3% 9.8%
ROE   12.4% 12.4% 7.8% 11.1% 14.2% 17.1% 17.0% 19.7% 19.5% 11.7%
ROTC   10.3% 12.2% 5.7% 8.4% 11.4% 12.8% 12.5% 14.6% 15.2% 10.0%
                       
TD / TC   8.1% 29.3% 26.1% 17.5% 10.5% 22.1% 15.4% 6.4% 1.3% 1.1%
                       
Days Receivables   67 53 70 62 58 58 64 64 60 62
Days Inventory   97 83 96 101 113 121 129 135 127 152
                       
Book / Bill   1.12 1.08 1.03 1.06 1.08 0.97 1.05 1.05 1.09 0.89
                       
Book Value   $2.41 $3.16 $3.41 $3.87 $4.48 $5.31 $5.71 $7.25 $9.52 $10.69
Tangible Book Value   $2.28 $1.98 $2.29 $2.71 $3.30 $3.44 $4.43 $5.98 $8.21 $9.42
                       
Net Debt (Cash) / Share   ($0.03) $1.02 $0.87 $0.28 ($0.21) $0.78 $0.14 ($0.58) ($2.26) ($3.06)

 

II-VI                          
Cash Flow Model                          
Fiscal Year End: June 30                      
In Millions, Except for Percentages & per Share Amounts                
Note: eV Products Classified as Discontinued Beginning FY08              
                           
    FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10E FY11E
                           
Net Income   7.3 9.5 7.3 11.6 17.3 24.8 10.8 38.0 65.7 38.9 34.6 55.4
Depreciation   4.7 6.8 8.4 8.8 9.0 11.5 14.3 15.4 14.2 14.1 17.6 17.4
Amortization   0.3 1.9 0.4 0.5 0.6 1.2 1.5 1.4 1.4 1.3 3.2 3.2
Stock Based Comp.               2.4 3.4 4.0 5.0 8.9 7.0
Other               17.6   (26.5)      
Cash Flow   12.3 18.2 16.1 20.9 27.0 37.5 46.6 58.1 58.7 59.2 64.2 83.0
                           
Capital Expenditures   8.9 16.7 8.7 7.0 12.7 17.7 15.6 20.2 17.9 15.6 15.5 22.4
Free Cash Flow   3.5 1.5 7.4 13.9 14.2 19.9 31.0 37.9 40.9 43.6 48.7 60.6
                           
Interest Expense   0.3 2.3 1.4 0.8 0.4 0.9 1.8 1.0 0.2 0.2 0.1 0.0
Income Taxes   2.4 5.1 2.2 4.4 7.1 9.1 10.7 12.2 24.9 7.4 12.8 20.5
EBITDA   15.1 25.6 19.7 26.2 34.5 47.6 59.1 71.3 83.9 66.7 77.1 103.5
                           
                           
Diluted EPS   $0.28 $0.34 $0.25 $0.40 $0.59 $0.83 $0.93 $1.25 $1.63 $1.19 $1.20 $1.77
CF / Share   $0.47 $0.64 $0.56 $0.73 $0.92 $1.26 $1.56 $1.92 $1.93 $1.96 $2.10 $2.65
FCF / Share   $0.13 $0.05 $0.26 $0.48 $0.48 $0.67 $1.04 $1.25 $1.34 $1.45 $1.59 $1.93
EBITDA / Share   $0.57 $0.90 $0.69 $0.91 $1.17 $1.59 $1.98 $2.35 $2.75 $2.21 $2.52 $3.30
                           
Est. Int. Inc. / Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.04 $0.05 $0.00 $0.00 $0.01
                           
                           
                  Stock Price $29.70  
                  Cash & Equivalents 97.2  
                  Total Debt 3.2  
                  Dil. Shares Out. 31.2  
                      Net Debt (Cash) Per Share ($3.01)  
                       
                  Net P/E 22.3 15.2
                  Net P/FCF 16.8 13.9
                  EV / EBITDA 10.6 8.1

 

LONG TERM PROJECTIONS. . .

II-VI                      
EPS Model                      
Fiscal Year End: June 30                      
In Millions, Except for Percentages & per Share Amounts            
Note: eV Products Classified as Discontinued Beginning FY06          
                       
    FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10E
                       
Sales                      
Infrared Optics   69.9 61.8 73.6 87.7 101.3 120.4 132.8 151.9 130.9 134.5
Near-Infrared Optics   25.1 22.7 22.8 25.8 33.9 34.0 50.3 58.7 45.6 82.9
Military & Materials   19.0 22.0 23.0 25.3 27.3 29.4 27.1 50.5 57.0 63.2
Compound Semi Group   9.3 7.1 8.7 12.1 31.5 39.9 44.6 55.1 58.7 53.4
Total Sales   123.3 113.7 128.2 150.8 194.0 223.6 254.7 316.2 292.2 333.9
                       
% Change (Yr./Yr.)                      
Infrared Optics     -11.5% 19.1% 19.0% 15.6% 18.9% 10.3% 14.4% -13.8% 2.7%
Near-Infrared Optics     -9.6% 0.5% 12.9% 31.5% 0.2% 47.9% 16.8% -22.4% 81.9%
Military & Materials     15.8% 4.5% 10.1% 7.9% 7.6% -7.7% 86.3% 12.9% 10.8%
Compound Semi Group     -23.7% 22.6% 38.5% 160.7% 54.7% 11.8% 23.6% 6.6% -9.1%
Total Sales     -7.8% 12.8% 17.7% 28.6% 19.8% 13.9% 24.2% -7.6% 14.3%
                       
Operating Income                      
Infrared Optics   13.7 12.7 20.0 23.6 32.7 34.5 35.7 36.2 28.0 24.5
Near-Infrared Optics   3.4 1.3 1.7 2.4 2.3 2.1 6.8 11.9 7.1 13.4
Military & Materials   3.6 1.6 (0.1) 0.9 1.0 0.1 2.5 7.1 6.5 8.1
Compound Semi Group   (2.4) (4.1) (4.4) (2.0) (1.5) 2.5 4.0 6.5 6.2 4.2
Total Op. Income   18.3 11.4 17.2 24.8 34.6 39.2 49.0 61.7 47.8 50.1
                       
Operating Margin                      
Infrared Optics   19.7% 20.5% 27.1% 26.9% 32.3% 28.7% 26.9% 23.8% 21.4% 18.2%
Near-Infrared Optics   13.4% 5.6% 7.4% 9.1% 6.8% 6.1% 13.5% 20.3% 15.6% 16.2%
Military & Materials   18.8% 7.2% -0.3% 3.5% 3.8% 0.4% 9.3% 14.0% 11.4% 12.8%
Compound Semi Group   -25.7% -58.1% -50.5% -16.3% -4.7% 6.2% 8.9% 11.8% 10.5% 7.8%
Total Op. Margin   14.8% 10.0% 13.4% 16.5% 17.8% 17.5% 19.2% 19.5% 16.4% 15.0%
                       
Interest Expense   2.3 1.4 0.8 0.4 0.9 1.8 1.0 0.2 0.2 0.1
Other Expense, Net   1.4 0.4 0.3 0.0 (0.3) (1.3) (2.7) (2.8) 1.4 (0.1)
Impairments & Other             16.8   (26.5)   2.8
                       
EBT   14.6 9.5 16.1 24.4 34.0 21.8 50.7 90.6 46.3 47.3
% of Sales   11.8% 8.4% 12.5% 16.2% 17.5% 9.8% 19.9% 28.7% 15.8% 14.2%
                       
Income Tax Expense   5.1 2.2 4.4 7.1 9.1 10.7 12.2 24.9 7.4 12.8
Rate   34.8% 23.6% 27.6% 29.0% 26.8% 49.2% 24.2% 27.5% 16.0% 27.0%
                       
Minority Interests                     (0.1)
                       
N.I. from Cont. Ops.   9.5 7.3 11.6 17.3 24.8 11.1 38.4 65.7 38.9 34.7
ex. Non-Rec.             28.0   49.8 35.8 36.7
                       
Earnings from Discont. Ops.           (0.3) (0.5) (1.4) (2.1)  
                       
Net Income   9.5 7.3 11.6 17.3 24.8 10.8 38.0 64.3 36.8 34.7
ex. Non-Rec.             27.7   48.4 33.7 36.0
                       
Diluted EPS from Cont. Ops. $0.34 $0.25 $0.40 $0.59 $0.83 $0.37 $1.27 $2.15 $1.29 $1.13
ex. Non-Rec.             $0.94   $1.63 $1.19 $1.20
                       
% Change (Yr./Yr.)     -24.3% 59.1% 45.9% 41.0% 12.8% 35.4% 28.6% -27.3% 1.0%
                       
Diluted EPS   $0.34 $0.25 $0.40 $0.59 $0.83 $0.36 $1.25 $2.11 $1.22 $1.13
ex. Non-Rec.             $0.93   $1.59 $1.12 $1.18
                       
Est. Interest Inc. / Share   $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.04 $0.05 $0.00 $0.00
                       
Diluted Shares Out.   28.3 28.6 28.8 29.4 29.9 29.9 30.3 30.5 30.1 30.6
% Change (Yr./Yr.)     1.1% 0.5% 2.3% 1.6% 0.0% 1.3% 0.7% -1.1% 1.5%

II-VI                            
EPS Model                            
FY End: June 30                            
In Millions, Except for Percentages & per Share Amounts                
Note: eV Products Classified as Discontinued Beginning FY06                
            Conservative Scenario   Aggressive Scenario
    FY08 FY09 FY10E   FY11E FY12E FY13E FY14E   FY11E FY12E FY13E FY14E
                             
Sales                            
Infrared Optics   151.9 130.9 134.5   158.7 171.4 185.1 199.9   161.4 177.5 193.5 210.9
Near-Infrared Optics   58.7 45.6 82.9   126.0 133.5 140.2 147.2   128.0 137.0 145.2 153.9
Military & Materials   50.5 57.0 63.2   68.9 73.7 79.2 87.1   69.5 74.7 81.1 90.8
Compound Semi Group   55.1 58.7 53.4   58.2 61.1 64.1 67.3   59.2 62.8 66.5 70.5
Total Sales   316.2 292.2 333.9   411.7 439.7 468.6 501.6   418.1 452.0 486.3 526.2
                             
% Change (Yr./Yr.)                            
Infrared Optics   14.4% -13.8% 2.7%   18.0% 8.0% 8.0% 8.0%   20.0% 10.0% 9.0% 9.0%
Near-Infrared Optics   16.8% -22.4% 81.9%   52.0% 6.0% 5.0% 5.0%   54.5% 7.0% 6.0% 6.0%
Military & Materials   86.3% 12.9% 10.8%   9.0% 7.0% 7.5% 10.0%   10.0% 7.5% 8.5% 12.0%
Compound Semi Group   23.6% 6.6% -9.1%   9.0% 5.0% 5.0% 5.0%   11.0% 6.0% 6.0% 6.0%
Total Sales   24.2% -7.6% 14.3%   23.3% 6.8% 6.6% 7.0%   25.2% 8.1% 7.6% 8.2%
                             
Operating Income                            
Infrared Optics   36.2 28.0 24.5   38.1 42.7 47.8 53.0   39.5 45.3 51.3 58.0
Near-Infrared Optics   11.9 7.1 13.4   20.2 21.4 22.4 23.6   20.9 22.3 23.7 25.1
Military & Materials   7.1 6.5 8.1   9.4 10.2 11.0 12.1   9.7 10.5 11.5 12.9
Compound Semi Group   6.5 6.2 4.2   6.4 6.7 7.1 7.4   6.7 7.1 7.5 8.0
Total Op. Income   61.7 47.8 50.1   74.1 80.9 88.2 96.0   76.8 85.2 94.0 104.0
                             
Operating Margin                            
Infrared Optics   23.8% 21.4% 18.2%   24.0% 24.9% 25.8% 26.5%   24.5% 25.5% 26.5% 27.5%
Near-Infrared Optics   20.3% 15.6% 16.2%   16.0% 16.0% 16.0% 16.0%   16.3% 16.3% 16.3% 16.3%
Military & Materials   14.0% 11.4% 12.8%   13.7% 13.8% 13.9% 13.9%   14.0% 14.1% 14.2% 14.2%
Compound Semi Group   11.8% 10.5% 7.8%   11.0% 11.0% 11.0% 11.0%   11.3% 11.3% 11.3% 11.3%
Total Op. Margin   19.5% 16.4% 15.0%   18.0% 18.4% 18.8% 19.1%   18.4% 18.9% 19.3% 19.8%
                             
Interest Expense   0.2 0.2 0.1   0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0
Other Expense, Net   (2.8) 1.4 (0.1)   (0.5) (1.0) (1.5) (2.0)   (0.5) (1.0) (1.5) (2.0)
Impairments & Other   (26.5)   2.8                    
                             
EBT   90.6 46.3 47.3   74.6 81.9 89.7 98.0   77.3 86.2 95.5 106.0
% of Sales   28.7% 15.8% 14.2%   18.1% 18.6% 19.2% 19.5%   18.5% 19.1% 19.6% 20.1%
                             
Income Tax Expense   24.9 7.4 12.8   20.1 22.1 24.2 26.5   20.9 23.3 25.8 28.6
Rate   27.5% 16.0% 27.0%   27.0% 27.0% 27.0% 27.0%   27.0% 27.0% 27.0% 27.0%
                             
Minority Interests       (0.1)   0.1 0.1 0.1 0.1   0.1 0.1 0.1 0.1
                             
N.I. from Cont. Ops.   65.7 38.9 34.7   54.3 59.7 65.4 71.5   56.4 62.8 69.6 77.2
ex. Non-Rec.   49.8 35.8 36.7                    
                             
Earnings from Discont. Ops. (1.4) (2.1)                      
                             
Net Income   64.3 36.8 34.7   54.3 59.7 65.4 71.5   56.4 62.8 69.6 77.2
ex. Non-Rec.   48.4 33.7 36.0                    
                             
Diluted EPS from Cont. Ops. $2.15 $1.29 $1.13   $1.73 $1.87 $2.01 $2.16   $1.80 $1.97 $2.14 $2.33
ex. Non-Rec.   $1.63 $1.19 $1.20                    
                             
% Change (Yr./Yr.)   28.6% -27.3% 1.0%   44.5% 7.9% 7.6% 7.3%   49.9% 9.6% 8.8% 9.0%
                             
Diluted EPS   $2.11 $1.22 $1.13   $1.73 $1.87 $2.01 $2.16   $1.80 $1.97 $2.14 $2.33
ex. Non-Rec.   $1.59 $1.12 $1.18                    
                             
Est. Interest Inc. / Share   $0.05 $0.00 $0.00   $0.01 $0.02 $0.03 $0.04   $0.01 $0.02 $0.03 $0.04
                             
Diluted Shares Out.   30.5 30.1 30.6   31.4 31.9 32.5 33.1   31.4 31.9 32.5 33.1
% Change (Yr./Yr.)   0.7% -1.1% 1.5%   2.5% 1.8% 1.8% 1.8%   2.5% 1.8% 1.8% 1.8%
                             
                             
Stock Price $29.70                    
Cash & Equivalents 97.2     142.8   197.6     144.9   203.6
Total Debt 3.2     0.0   0.0     0.0   0.0
Dil. Shares Out. 31.2     31.9   33.1     31.9   33.1
Net Debt Per Share ($3.01)     ($4.47)   ($5.97)     ($4.54)   ($6.15)
                             
Implied Multiples 22.3   15.5 14.4 13.5 12.6   14.9 13.7 12.6 11.6
                             
Assumed Exit Multiple       18.0   18.0     20.0   20.0
                             
Implied Exit Price       $37.76   $44.14     $43.49   $52.06
                             
Implied Annual Return       12.8%   10.4%     21.0%   15.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Catalyst

Economic improvement, numerous internal developments underway, low multiple.
    show   sort by    
      Back to top